FDA 483 OBSERVATION · #128 OF 1,923 MOST-CITED
Validation lacking for sterile drug products
FDA cited this observation 240 times across 208 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Written procedures to prevent microbiological contamination of drug products purporting to be sterile are lacking or inadequate — including validation of the sterilization process, aseptic processing, and any sterility-assurance controls required by §211.113(b).
Why FDA writes it — For a sterile product, sterility cannot be tested into the batch — it must be assured by a validated process. FDA protects against releasing supposedly-sterile drugs on the strength of an unvalidated or poorly validated process, where a contaminated unit reaching a patient can be fatal.
- Validate the sterilization or aseptic process with documented protocols, worst-case challenges, and defined acceptance criteria.
- Maintain media fills, environmental monitoring, and sterility-assurance controls with justified alert and action limits.
- Revalidate on significant changes to process, equipment, load, or facility, and on adverse trend signals.
- Have the quality unit review validation data and monitoring results before releasing any sterile batch.
- Aseptic process qualification relies on a one-time study never revalidated after line or load changes.
- Environmental and media-fill excursions are handled as isolated events rather than as validation-state signals.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 6.4× the rate of the average FDA-cited firm (49.5% vs 7.8%), across 208 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the sterilization process.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →